MarketPulse
D

$DNLI

4 articles found
2 positive
1 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Oligonucleotide Boom: 200+ Companies Race to Launch 600+ Pipeline Drugs

Over 200 companies are developing 600+ oligonucleotide therapies, with major players advancing late-stage trials and securing significant funding.
AMGNLLYNVSBIIBIONS+3clinical trialsgene therapy
The Motley FoolThe Motley Fool··Sara Appino

Privium Fund Bets $5M on Denali Ahead of FDA Approval Win

Privium Fund Management acquires $5.07M stake in Denali Therapeutics following FDA approval of first commercial drug Avlayah for Hunter syndrome treatment.
DNLIclinical trialsneurodegenerative diseases
BenzingaBenzinga··Vandana Singh

Takeda Exits Dementia Drug Partnership With Denali in Strategic Shift

Takeda exits dementia drug partnership with Denali Therapeutics on DNL593. Denali regains full control, plans Phase 1/2 data release by end-2026. Denali shares fell 3.73%.
TAKDNLIPhase 1/2 trialbiotech collaboration
BenzingaBenzinga··Usa News Group

$578B Regenerative Medicine Market Faces Manufacturing Crisis as Avaí Bio Pioneers Cell Banking Solution

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.
PRMEIOVAAVAIMDGLDNLIFDA approvalregenerative medicine